The European Directive on clinical trials of medicinal products will fall within the scope of the legislation of Member States on 1 May 2004. In France, this adaptation will be carried out by a public health bill concerning, among other things, the reform of the current Huriet-Sérusclat law, and by means of regulations. For trials concerning the initial administration of a product to human subjects, the group suggested the following recommendations:
Introduction
The European Directive on clinical trials of medicinal products [1] was adopted in May 2001 and will fall within the scope of the legislation of the Member States on 1 May 2004 at the very latest. At the time of this round table meeting, a French public health bill focusing on reform of the current Huriet-Sérusclat law [2] in its IV title was in progress. One or several decrees or orders will also be necessary to establish certain points that are not outlined in the bill. Besides these legislative and regulatory aspects, there is the issue of the practical feasibility of the pro- † For a list of participants, please see the end of the article. visions as they are envisaged in the individual countries, specifically the procedures for the initiation, development and termination of the trial as established by the directive and its guidance documents. [3] The challenges of this adaptation project focus on the need to maintain the appeal of France as a favourable place for conducting clinical trials, and particularly to continue to attract the international development of innovative medicinal products that will enable the medical community and asssociated experts to develop personal and local experience concerning these future products. As several surveys have shown, [4, 5] the HurietSérusclat law and the principle of notifying trials to Afssaps (Agence française de sécurité sanitaire des produits de santé) are part of a simple and predictable framework for trials that favours France. The continued differences between Member States concerning the transposition project may, on the contrary, be considered as an opportunity to consolidate this advance.
Phase I trials, limited in this sense to the initial administration of a new medicinal product in human subjects, represent an interesting and relatively simple working model, as well as a sensitive topic. Indeed, the start of phase I trials in France may result in the subsequent establishment of further trials using the same molecule.
The round table participants, who included academics, hospital specialists, and industry and legal experts, were aware of the challenges of the initial administration of a new active ingredient to healthy human subjects or patients (e.g., antineoplastic agents) or to specific populations (children). While keeping the specifics of these trials in mind, they formulated recommendations that aimed to optimise the implementation and development of such trials in France. Another objective was to facilitate the setting-up of a pilot phase by Afssaps.
Identification and Description of the Topic in France
It is useful to describe trials performed in France that involve the initial administration of medicinal products (Afssaps, unpublished data) .
Only a fraction of trials currently registered with the Clinical Trials Unit of Afssaps under the classification 'phase I' is relevant.
While a slight decrease may be detected in the total number of trials on medicinal products performed in France between 1998 and 2002 (-17%) , it is important to note that the proportion of phase I trials is itself stable. Of the 1227 trials of all phases registered in 2002, 297 or 24% were classified as phase I studies by the sponsors.
In 2002, 168 trials concerned new active ingredients (no marketing authorisation [MA] in either France or abroad), i.e. 57% of the total of registered trials. These 168 trials involved 110 active ingredients, of which 88 (81%) are exclusively studied as phase I; in other words, they would correspond to initial product administrations. We can see therefore that trials on initial product administrations represent barely 30% of registered phase I trials and 7% of all trials conducted nationally.
Moreover, 99% of phase I trials concerning new active substances are conducted by industry sponsors. In 2002, trials based on the criterion of sites authorised to conduct studies without direct individual benefit (DIB) were performed at private establishments in 64% of cases and at public establishments in 36% of cases. Forty percent of these authorised sites are located in Paris and the surrounding areas. Of the 1500 authorised sites for studies without DIB, 49 different sites were requested in 2002.
Phase I trials were performed at a single centre in 80% of cases, and of the 50 multicentre trials, half were international. In 2002, the number of participants in phase I trials was estimated to be 9600 in France, i.e. an average of 32 participants per trial.
This census was also able to show that approximately one of two phase I trials contains at least one amendment. This is an important fact, since the management of amendments regarded as 'substantial' stipulates a set of administrative constraints for the different players involved in the research. Their management will therefore be reflected in terms of the resources necessary for analysing these applications.
The Situation Abroad
The organisation of phase I trials abroad, both currently and in the future, was analysed by a subgroup of the round table by asking European subsidiaries of companies or persons responsible for evaluating clinical trials of Member States (appendix I) to complete a standard questionnaire. This survey has been published separately. [6] It is notable that some countries more specifically interested in phase I trials announced a shorter time period for examining dossiers within the context of their adaptation project of the European Directive. These deadlines should be considered within the 'competitive' context as indicated below:
• The Netherlands: 15 days for the opinion from the Ethics Committee (EC) and the authorisation from the competent authority. It is envisaged that the EC will handle a significant part of the scientific evaluation concerning the product of the trial.
• Great Britain: 14 to 21 days for the competent authority.
There is no precise indication as to whether the EC will provide its opinion within a deadline of fewer than 60 days.
• Germany: 30 days for the two opinions for a first product administration and 14 days for trials of subsequent phases. Moreover, a pilot phase for phase I studies that is intended to test the feasibility of the system has been set up in Great Britain.
Recommendations for France
The proposals concern the contents of a dossier for the initial request for authorisation of a trial -the investigational medicinal product (IMP) dossier, the protocol, the subject's information sheet -in addition to the definition of amendments that are substantial to a clinical trial and the procedures for declaring serious adverse events (SAEs) within the context of these initial phase I trials.
The group considered the analysis of measures put in place by the other Member States and the situation of phase I trials in France.
Proposals Concerning the Authorisation of Clinical Trials

Deadline for Evaluation and Respective Competencies
The members of the round table recommended that a deadline of 30 days be included in the adaptation text for the initial authorisation and that the period of validation concerning the competent authority (Afssaps) be shortened. Currently, the average deadline observed for the EC (Committee for the Protection of Persons [CPP] ) is 20 days (35 official days) and this should be maintained.
It appears especially essential for all to properly define the respective scopes of their activities.
After analysing the documents addressed to each of these bodies in accordance with the guidelines of the directive (table I), the group suggested the following distribution of activities: Afssaps to be specifically responsible for the complete evaluation of the IMP (quality, safety, methods for use in the trial); and the CCP to be responsible for aspects relating to the information on and protection of participants, and the adequacy of the facilities. The two bodies could be called on to express their opinion on the trial protocol.
Contents of the Initial Request Dossier
The dossier for the request for authorisation of a clinical trial consists of the following three principal elements:
• the trial protocol and its appendices;
• the subject/patient information sheet and the consent form;
• the investigational medicinal product dossier (IMPD).
Protocol
Principally, the content of the protocol will be based on the table of contents provided for in the 'Good Clinical Practices' (GCP), as presented in the International Committee on Harmonisation (ICH) E6 text adopted by the European Agency for the Evaluation of Medicinal Products (EMEA) [7] [appendix II].
It is important that certain aspects of these provisions are adapted and confirmed in phase I trials. These are as follows:
• the name and description of the IMP tested;
• the summary of the nonclinical data with clinical relevance for the trial;
• the summary of known or potential risks in humans;
• the justification of routes of administration, doses and the dosage regimen;
• the duration of participation for subjects;
• the description of the rules for trial discontinuation relating to both a subject and the trial;
• previous and concomitant treatments that are or are not allowed;
• quality control and assurance.
However, the group recommends that the following ten points be systematically completed for phase I trials, and that they possibly become the subject of a separate document:
• a general justification of the trial with a summary of information gathered on the IMP; • justification of the galenic form and the route of administration;
• justification of the choice of the first dose administered;
• justification of the dose-escalation scheme;
• justification of the treatment duration for a subject in relation to the preclinical dossier;
• details of the objectives of the study (knowledge of doses used, pharmacokinetics, mechanism of action, interaction with other medicinal products, etc.);
• details and justification of criteria for evaluating efficacy and safety assessment in relation to preclinical data (target organs, duration of effect, etc.);
• justification of the duration of monitoring for each subject or patient;
• details and, if necessary, justification of the 'warning' procedures: -clinical (calling the resuscitation team) -methodology (breaking the randomisation code) -and procedures for discontinuing treatment for a subject or stopping the trial;
• in the case of administration to a patient: justification for choosing a patient rather than a healthy volunteer. Such a document could help speed up the receipt of the opinion, especially from the CPP.
Information and Consent
The current provisions already contain several essential and explicit elements. It is suggested that certain details be added concerning the following:
• the collection and preservation of biological samples, especially with regard to their future use;
• the means by which the subject could be informed of the global results at the end of the research;
• information allowing the subject direct access to insurance;
• the principle of separate consent for the ancillary studies, if these involve additional measures.
Investigational Medicinal Product Dossier (IMPD)
It was recalled that, in July 2003, Afssaps developed and posted on its website (www.afssaps.sante.fr) recommendations on the content of the parts relating to the pharmaceutical and nonclinical data for the IMPD in phase I trials. During the round table meeting, these recommendations as well as comments derived from public consultations were presented and discussed.
Certain particularly important points with regard to phase I trials emerged from the debate:
• Pharmaceutical quality: Overall, it concerns justifying administration to humans at this stage in the knowledge of the product's pharmaceutical quality. It is quite clear that studies with the aim of demonstrating quality are not yet complete, that the formulation of the medicinal product is only provisional, and that the dose administered in clinics is not defined. Nevertheless, safety of administration needs to be ensured by providing a description of the minimum necessary data, some of which are essential (table II) . If the format selected by the guidance document is that of the 'Common Technical Document' (CTD), [8] the essential data will obviously entail all available information on the drug substance, the IMP (provisional), and the comparator product, including the placebo. Whenever possible, a cross-reference to the List of principal investigators and coordinator Quality of the site(s), authorisations for the research sites CV of coordinator and principal investigators, information on personnel and facilities CTD = Common Technical Document; CV = curriculum vitae; EMEA = European Agency for the Evaluation of Medicinal Products; GMO = genetically modified organism; GMP = good manufacturing practices; IB = Investigator Brochure; MS = Member States.
Pharmacopoeia will be provided. All the relevant points relating to stability will be provided. An analytical method will need to be available and validated. Knowledge, even if only partial, of the principal impurities is required. In relation to the table of contents of the CTD, omission of any essential information needs to be justified. It is important to remember that, in the case of an MA, the IMPD is simplified. Thus, for the comparator, in the case of simple 'masking' and re-packaging, the product reference, product description (Summary of Product Characteristics [SPC] ) and description of capsules will be accepted.
• Nonclinical part: Unlike the principal pharmaceutical data, the nonclinical data are generally included in every 'Investigator's Brochure'. By way of a reminder, the standard content of the Investigator's Brochure is described in the ICH GCP under the item 'Essential Documents'. [7] The theoretical format of the nonclinical part of the IMPD is also that of the CTD, but cross-references may be made with the Investigator's Brochure. This section should describe the specific pharmacological data supporting the future indication of the product and, when known, the precise mechanism of action. It should also contain all the elements relating to safety pharmacology, describing the effect of the product on different organs (heart, central and peripheral nervous systems, kidneys, liver) and studies performed in certain body systems in relation to a particular exposure resulting from a specific concentration of the product in certain organs, e.g., the endocrine glands, testicles and ovaries, the eye, and the auditory system; hence the importance of radiolabelling studies. Data on pharmacokinetics and metabolism should be provided together with the metabolites likely to be observed in humans (and, ideally, the assay method used), such as those determined in studies in human hepatocytes. The following should also be provided: the 'toxicokinetic' data and the rationale for the choice of animal models, and the doses prescribed in the toxicology studies based on the analysis of this data; the single-dose toxicity data and repeat-dose toxicity to the species selected; the genotoxicity data (in vitro and in vivo) and the reproductive data -at least data relating to the segment of fertility studies (segment 1) with 'testicular staging'. Finally, data on local tolerability in relation to the route of administration (injection, inhalation in particular) should also be provided. The essential points of the discussion concerning the nonclinical data are summarised in table III. [9, 10] • Clinical part: At this stage, it is generally limited. Every previous product administration should be registered and duly described with respect to product safety (the number, nature and intensity of adverse reactions per subject and dose level). The data should also be available.
Proposals Concerning Substantial Amendments
By 'substantial', the guidance document [3] indicates any amendments that are likely to have a significant impact on the following:
• the safety or physical or mental integrity of the subjects;
• the scientific value of the trial;
• the conduct or management of the trial;
• the quality or safety of any IMP used in the trial.
Moreover, certain examples are provided (in attachment 5 of the guidance document).
The group's recommendation was to use the definition terms very precisely and in an inclusive way, namely: 'The sponsor should determine for each case whether the amendment is substantial by referring to the criteria of definition AND the provided examples'.
Proposals Concerning the Management of Adverse Reactions During First Product Administration Trials
Given that phase I trials have a collective objective which, allowing for some exceptions, does not conform to an individual therapeutic perspective, these trials should not involve any serious predictable risk for anyone participating. This is the reason for the following recommendations of the round table meeting:
• the investigator immediately reports any SAEs to the sponsor, without any exceptions;
• after lifting the systematic blinding, the SAE is reported by the sponsor to the competent authority insofar as it concerns the IMP, or the conditions of the trial (and in the case of any impact on the safety of participants), or insofar as no cause (for the SAE) can be determined;
• the investigators are informed as soon as possible;
• as outlined in the corresponding guidance document, [11] a trial safety report should be sent within a maximum of 90 days after the end of the trial.
Other Aspects of the Adaptation, and Specifically Logistical Aspects
Authorisation of Research Sites
Some countries will maintain or establish within their national system an authorisation for research sites. This is the case for France, Spain, Italy and Greece. It is likely that a similar recommendation may be actioned in Great Britain.
With regard to France, the revision project of the HurietSérusclat law is to maintain authorisation for the sites that perform research that deviates from their primary remit of healthcare. Ipso-facto, the majority of sites where phase I studies are conducted should continue to be authorised. Nevertheless, this should not apply to the phase I trials in oncology conducted at specialist centres.
Register of Subjects
Great Britain and Germany have set up a pilot phase for establishing these subject registers. In France, the principle of the existing register for healthy volunteers should be renewed.
Laboratory Examinations
Certain countries request authorisation for sites where laboratory examinations are performed. This issue is being considered in France for the assays that fall outside of the usual tests carried out by the laboratories performing medical and biological analyses.
Insurance
Previously covered in France by the 'no-fault compensation' system, subjects participating in phase I trials, as is the case with subjects and patients in any clinical trial, will now be covered by the 'presumed fault' system. This will allow the sponsor, if nec- Table III . Nonclinical data (points having been the subject of in-depth discussions) Quality assurance and toxicology It emerged from the discussion that, in the case of a lack of any final audited reports (especially toxicology), raw audited data available to the sponsor and a submission of an interim report would be considered as an acceptable minimum substitute.
Duration of the studies
If the product administration is limited to a single dose, the duration of exposure (toxicity known as 'subacute') will be 14 days in the two animal species. It was highlighted that these last two requirements were nevertheless 'higher' than those required by the US FDA. [9] For the rest, the length of exposure necessary in animals in order to move into the clinical stage is in agreement with the recommendations of the ICH M3. [10] Assessment of radioactivity and analytical method Concerning kinetics, the importance is stressed of having a radiolabelled pharmaceutical assessment in animals and a validated analytical method in order to be able to administer dosages in humans within the same or slightly delayed time-frame. US FDA = US Food and Drug Administration; ICH = International Committee on Harmonisation.
essary, to withdraw liability should it not be responsible for the accident recorded.
The situation of subjects not covered by this type of insurance should be examined by the compensation committee responsible to the State under the principle of unknown therapeutic benefits in accordance with the law dated 4 March 2002. [12] 
Compensation for Subjects
It is likely that the law will adapt the provision of the directive that establishes compensation to subjects for any 'constraints suffered'. It will be the responsibility of the CPP to evaluate whether the level of compensation is adequate, which will also be reported in the register of subjects.
Distribution System and Conditions of Use of Investigational Medicinal Products
Some questions remain unresolved, such as the conditions under which a phase I research centre may import, release, package and label the IMPDs. These are pharmaceutical activities that need to be performed by institutions authorised in this field. Discussions are underway that aim to determine whether or not authorisation of the research could apply, under certain conditions, to the manufacture of the product for the duration of the research only. Moreover, a system suitable for authorisation of packaging and labelling for research where the posology may not be known in advance (e.g. determination of the maximum tolerated dose), is being examined.
Transition Phase
As has been mentioned, certain countries (notably Great Britain) have set up a pilot phase of transition followed by the system finally selected.
France is launching a voluntary pilot phase, the details of which can be found on the Afssaps website (www.afssaps. sante.fr).
The aim of this pilot phase is to simulate the authorisation of a clinical trial by the Agency, allowing the different stakeholders to prepare the request dossier and Afssaps to prepare its evaluation within a period of 30 days. Afssaps circulates the list of documents to be provided and the procedure to be followed. This pilot phase is initially limited to phase I trials of medicinal products, with cell and gene therapies excluded.
An adjusted report is expected.
Conclusion and Summary of the Recommendations
The group issued recommendations enabling practical variations in the provisions of the European Directive of clinical trials, the adaptation of which in the legislation of the Member States should come into force during 2004.
The most significant of these recommendations are as follows:
• In the French texts, to include a deadline of 30 days for the initial authorisation of Afssaps and to maintain an observed deadline of 20 days (35 official days) for a positive decision from the CPP.
• To properly distribute the respective functions of Afssaps and the CPP, with evaluation of the medicinal product being the exclusive responsibility of Afssaps.
• To submit a protocol in the ICH format and adapted for the particular case of phase I trials, by specifically justifying the trial on the basis of the knowledge acquired regarding the product, the choice of the first dose and the dosage regimen, the measures for the protection of subjects and the conditions relating to warnings and termination of treatment or of the entire study. Ten principal elements could constitute a separate document.
• The content of the IMPD would follow the conditions posted on the website of Afssaps, by insisting on certain pharmaceutical (acceptable level of quality at this stage of product development) and nonclinical (pre-required and data proving to be especially useful in this type of trial) points.
• To follow precisely and exclusively the guidance document when submitting substantial amendments.
• To break the blind for every SAE reported by the investigator to the sponsor and to report to Afssaps every SAE related to the IMP or the trial, or even SAEs with no obvious cause, while also keeping the investigators informed.
• The remaining provisions set out in the directive or the adaptation texts will be applicable, but some unresolved questions remain concerning the authorisations allowed for the distribution system for IMPs, especially in these early studies.
